R&D is a major activity of “Pneumogenesis”. On-going research is focusing on stem cell function, including immunomodulatory, anti-fibrotic and regenerative capacity of mesenchymal stem cells. Future contributions will include new patented products and therapeutic interventions, including the launching of the new scientific field of stem cell “secretomics”; one of our major milestones.


Technological landmarks


The approach we are using is a multi-disciplinary one, including specialists from diverse medical fields (pneumonology, pharmacology, intensive care) and basic research scientists including a clinical biochemist/toxicologist, a molecular biologist and a bioinformatician. Our clinical platform includes: a) diagnostic criteria established by ATS/ERS, b) pharmacological interventions, c) operational procedures (i.e. bronchoscopy) and d) post-infusion curative treatment. Our clinical protocol involves optimization of stem cells prior to transplantation including the selection of sub-populations of stem cells expressing specific biomarkers with the use of flow cytometry. Artificial intelligence algorithms are used to model disease parameters and predict the most efficient curative scheme.

This site uses Akismet to reduce spam. Learn how your comment data is processed.